Evidence map›Paper›PMID 39542943›Full record

ArticleDiscover nano2024

Effects of nanocapsules containing lumefantrine and artemether in an experimental model of cerebral malaria.

Bianca Portugal Tavares de Moraes, Karoline Paiva da Silva, Karina Paese, Adilson Paulo Sinhorin, Silvia S Guterres, Adriana R Pohlmann, Isabelle Moraes-de-Souza, Sarah de Oliveira Rodrigues, Kauê Francisco Corrêa E SouzaSouza, Carolina Medina Coeli da Cunha and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Bianca Portugal Tavares de Moraes *Post-Graduation Program in Neuroscience, Fluminense Federal University, Rio de Janeiro, Brazil.
Karoline Paiva da Silva *Health Sciences Post-Graduation Program, Federal University Mato Grosso, Sinop, 78550-728, Brazil.
Karina PaeseEnvironmental SciencesPost-Graduation Program, Federal University of Mato Grosso, Sinop, 78550-728, Brazil.
Adilson Paulo SinhorinEnvironmental SciencesPost-Graduation Program, Federal University of Mato Grosso, Sinop, 78550-728, Brazil.
Silvia S GuterresPharmaceutical Sciences Post-Graduation Program, Federal University of Rio Grande Do Sul, Porto Alegre, 90610-000, Brazil.
Adriana R PohlmannPharmaceutical Sciences Post-Graduation Program, Federal University of Rio Grande Do Sul, Porto Alegre, 90610-000, Brazil.
Isabelle Moraes-de-SouzaImmunopharmacology Laboratory, Federal University of State of Rio de Janeiro, Rio de Janeiro, Brazil.
Sarah de Oliveira RodriguesImmunopharmacology Laboratory, Federal University of State of Rio de Janeiro, Rio de Janeiro, Brazil.
Kauê Francisco Corrêa E SouzaSouzaImmunopharmacology Laboratory, Federal University of State of Rio de Janeiro, Rio de Janeiro, Brazil.
Carolina Medina Coeli da CunhaImmunopharmacology Laboratory, Oswaldo Cruz Institut, Rio de Janeiro, Brazil.
Matheus Augusto Patrício de AlmeidaImmunopharmacology Laboratory, Oswaldo Cruz Institut, Rio de Janeiro, Brazil.
Patrícia Torres BozzaImmunopharmacology Laboratory, Oswaldo Cruz Institut, Rio de Janeiro, Brazil.
Hugo Caire de Castro-Faria-NetoImmunopharmacology Laboratory, Oswaldo Cruz Institut, Rio de Janeiro, Brazil.
Adriana Ribeiro SilvaPost-Graduation Program in Neuroscience, Fluminense Federal University, Rio de Janeiro, Brazil.
Cassiano Felippe Gonçalves-de-Albuquerque *Immunopharmacology Laboratory, Federal University of State of Rio de Janeiro, Rio de Janeiro, Brazil. cassiano.albuquerque@unirio.br.
Stela Regina Ferrarini *Health Sciences Post-Graduation Program, Federal University Mato Grosso, Sinop, 78550-728, Brazil. srferrarini@gmail.com.

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) 001Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/010.000983/2019Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) E-26/203.290/2017
6 · The paper itself

Abstract

backgroundMalaria, a tropical neglected disease, imposes a significant burden on global health, leading to the loss of thousands of lives annually. Its gold standard treatment is a combination therapy of lumefantrine (LUM) and artemether (ART). Nanotechnology holds significant potential for improving drug bioavailability and potency while reducing adverse effects.

objectivesThis study aimed to develop lipid-core nanocapsules containing ART and LUM and evaluate their effects in an experimental cerebral malaria model (ECM).

methodsThe polymeric interfacial deposition method was used to develop lipid-core nanocapsules (LNCs) containing ART and LUM (LNC

resultsLNCs were successfully developed and characterized. The treatment with LNC

conclusionNanoformulations can potentially improve the efficacy of antimalarial drugs and be considered a promising approach to treat malaria.

Indexed as

ArtemetherCerebral malariaLipid core nanocapsulesLumefantrineMicrocirculation

Identifiers

PMID39542943
PMCPMC11564608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.